JP2016503295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503295A5 JP2016503295A5 JP2015540250A JP2015540250A JP2016503295A5 JP 2016503295 A5 JP2016503295 A5 JP 2016503295A5 JP 2015540250 A JP2015540250 A JP 2015540250A JP 2015540250 A JP2015540250 A JP 2015540250A JP 2016503295 A5 JP2016503295 A5 JP 2016503295A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 239000000611 antibody drug conjugate Substances 0.000 claims 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 230000027455 binding Effects 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 16
- 101001003132 Homo sapiens Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723545P | 2012-11-07 | 2012-11-07 | |
| US61/723,545 | 2012-11-07 | ||
| US201361749610P | 2013-01-07 | 2013-01-07 | |
| US61/749,610 | 2013-01-07 | ||
| US201361886156P | 2013-10-03 | 2013-10-03 | |
| US61/886,156 | 2013-10-03 | ||
| US201361889179P | 2013-10-10 | 2013-10-10 | |
| US61/889,179 | 2013-10-10 | ||
| PCT/IB2013/059786 WO2014072888A1 (en) | 2012-11-07 | 2013-10-30 | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503295A JP2016503295A (ja) | 2016-02-04 |
| JP2016503295A5 true JP2016503295A5 (OSRAM) | 2016-12-22 |
Family
ID=49955428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540250A Pending JP2016503295A (ja) | 2012-11-07 | 2013-10-30 | 抗ｉｌ−１３受容体アルファ２抗体および抗体−薬物コンジュゲート |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9828428B2 (OSRAM) |
| EP (1) | EP2916875A1 (OSRAM) |
| JP (1) | JP2016503295A (OSRAM) |
| KR (1) | KR101763499B1 (OSRAM) |
| CN (1) | CN104936621A (OSRAM) |
| AU (1) | AU2013343111A1 (OSRAM) |
| CA (1) | CA2890256A1 (OSRAM) |
| HK (1) | HK1214161A1 (OSRAM) |
| IL (1) | IL238566A0 (OSRAM) |
| MX (1) | MX2015005582A (OSRAM) |
| PE (1) | PE20150891A1 (OSRAM) |
| PH (1) | PH12015500977A1 (OSRAM) |
| RU (1) | RU2015116485A (OSRAM) |
| SG (1) | SG11201503431TA (OSRAM) |
| WO (1) | WO2014072888A1 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| PE20160953A1 (es) * | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| ES2883023T3 (es) | 2014-05-28 | 2021-12-03 | Agensys Inc | Derivados de péptidos de dolaproína-dolaisoleuina citotóxicos para el tratamiento del cáncer |
| NZ726520A (en) | 2014-05-29 | 2018-12-21 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
| KR20240091253A (ko) | 2015-02-16 | 2024-06-21 | 론자 리미티드 | Cl 및/또는 ch1 돌연변이된 약물 접합용 항체 |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| TWI703160B (zh) * | 2015-11-30 | 2020-09-01 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| TWI778491B (zh) | 2015-11-30 | 2022-09-21 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| TW202208440A (zh) | 2015-12-14 | 2022-03-01 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
| WO2017107817A1 (zh) * | 2015-12-21 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
| WO2017117464A1 (en) * | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| CN108456250B (zh) | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CN107880131A (zh) * | 2017-08-14 | 2018-04-06 | 四川大学 | 一种抗IL‑13Rα2和CD3双特异抗体及其应用 |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| JP2021505637A (ja) | 2017-12-12 | 2021-02-18 | マクロジェニクス，インコーポレーテッド | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |
| AU2019222666B2 (en) | 2018-02-15 | 2025-12-04 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| EP4491718A3 (en) | 2018-03-14 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
| EA202091982A1 (ru) * | 2018-03-14 | 2021-06-10 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии |
| TWI756633B (zh) * | 2019-02-15 | 2022-03-01 | 大陸商上海藥明生物技術有限公司 | 具有改善的同質性的抗體－藥物綴合物、其藥物組合物、用途和製備方法 |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4106813A4 (en) | 2020-02-21 | 2024-03-27 | MacroGenics, Inc. | CD137 BINDING MOLECULES AND THEIR USES |
| JP2023525226A (ja) * | 2020-05-15 | 2023-06-15 | エリセラ セラピューティクス アクチエボラグ | 抗ＩＬ１３Ｒα２抗体、その抗原結合フラグメントおよび使用 |
| GB202011993D0 (en) * | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| CN117043192B (zh) * | 2021-02-19 | 2024-05-03 | 上海齐鲁制药研究中心有限公司 | 针对IL-13Rα2的抗体及其应用 |
| KR20240027117A (ko) | 2021-07-01 | 2024-02-29 | 닝보 티-맥시멈 바이오파마슈티컬스 컴퍼니 리미티드 | B7h3을 표적으로 하는 항원 결합 폴리펩티드 및 이의 응용 |
| CN115768445A (zh) * | 2021-07-01 | 2023-03-07 | 宁波茂行生物医药科技有限公司 | 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用 |
| CN118843643A (zh) * | 2022-02-17 | 2024-10-25 | 上海礼新医药研发有限公司 | 抗il-13ra2单克隆抗体及其用途 |
| WO2024041650A1 (en) * | 2022-08-25 | 2024-02-29 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| CN120882864A (zh) * | 2022-09-30 | 2025-10-31 | 国立大学法人 东京大学 | 靶向il13ra2的单纯疱疹病毒及抗il13ra2抗体或其抗原结合片段 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004511425A (ja) | 2000-02-08 | 2004-04-15 | ザ ペン ステート リサーチ ファウンデーション | 免疫療法に使用されるインターロイキン１３受容体サブユニットアルファー２ |
| AU2001284978A1 (en) * | 2000-08-31 | 2002-03-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain |
| WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| WO2005042028A2 (en) | 2003-10-27 | 2005-05-12 | Neopharm, Inc. | Il-13 conjugated to an immunogen and uses thereof |
| PL2068922T3 (pl) | 2006-10-19 | 2012-11-30 | Csl Ltd | Przeciwciała anty-IL-13R alfa1 i ich zastosowania |
| PL2068921T3 (pl) | 2006-10-19 | 2014-12-31 | Csl Ltd | Przeciwciała o dużym powinowactwie będące antagonistami receptora alfa1 interleukiny 13 |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| EP2593142B8 (en) | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
| PT3327027T (pt) | 2011-11-17 | 2021-02-15 | Pfizer | Péptidos citotóxicos e seus conjugados de anticorpos e fármacos |
| WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| TW201341401A (zh) | 2012-01-09 | 2013-10-16 | Covx Technologies Ireland Ltd | 突變抗體及其共軛 |
-
2013
- 2013-10-30 AU AU2013343111A patent/AU2013343111A1/en not_active Abandoned
- 2013-10-30 CN CN201380057103.5A patent/CN104936621A/zh active Pending
- 2013-10-30 SG SG11201503431TA patent/SG11201503431TA/en unknown
- 2013-10-30 HK HK16102252.1A patent/HK1214161A1/zh unknown
- 2013-10-30 PE PE2015000568A patent/PE20150891A1/es not_active Application Discontinuation
- 2013-10-30 US US14/439,897 patent/US9828428B2/en active Active
- 2013-10-30 WO PCT/IB2013/059786 patent/WO2014072888A1/en not_active Ceased
- 2013-10-30 MX MX2015005582A patent/MX2015005582A/es unknown
- 2013-10-30 KR KR1020157011436A patent/KR101763499B1/ko not_active Expired - Fee Related
- 2013-10-30 RU RU2015116485A patent/RU2015116485A/ru not_active Application Discontinuation
- 2013-10-30 JP JP2015540250A patent/JP2016503295A/ja active Pending
- 2013-10-30 EP EP13820931.7A patent/EP2916875A1/en not_active Withdrawn
- 2013-10-30 CA CA2890256A patent/CA2890256A1/en not_active Abandoned
-
2015
- 2015-04-30 IL IL238566A patent/IL238566A0/en unknown
- 2015-04-30 PH PH12015500977A patent/PH12015500977A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503295A5 (OSRAM) | ||
| RU2015116485A (ru) | Антитела к рецептору альфа 2 интерлейкина-13 и конъюгаты антитело-лекарственное средство | |
| JP2020023523A5 (OSRAM) | ||
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| JP2010535713A5 (OSRAM) | ||
| JP2019512242A5 (OSRAM) | ||
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| JP2022512132A (ja) | 抗クローディン抗体及びそれらの使用 | |
| ES2662418T3 (es) | Agentes de unión a TNF mejorados | |
| JP2020502271A5 (OSRAM) | ||
| JP2017186337A5 (OSRAM) | ||
| RU2013142004A (ru) | Конъюгаты "антитело-лекарственное средство" | |
| JP2018504105A5 (OSRAM) | ||
| JP2011505146A5 (OSRAM) | ||
| JP2017531028A5 (OSRAM) | ||
| JP2020511936A5 (OSRAM) | ||
| JP2008532523A5 (OSRAM) | ||
| JP2015516985A5 (OSRAM) | ||
| JP2013502913A5 (OSRAM) | ||
| JP2009506790A5 (OSRAM) | ||
| JP2012100677A5 (OSRAM) | ||
| JP2010511388A5 (OSRAM) | ||
| JP2009505676A5 (OSRAM) | ||
| IL278574B2 (en) | Glycan-interacting compounds and methods of use | |
| JP2016523810A5 (OSRAM) |